Short-Acting Beta2-Agonists (SABA) Market Scope and Opportunities Analysis 2025
Short-acting beta2-agonists (SABA) are a type of bronchodilators. These are the most common immediate-relief drugs for treating asthma attacks and to manage both acute and stable exacerbations of chronic obstructive pulmonary disease (COPD). Salbutamol is the most commonly prescribed short-acting beta2-agonists (SABA) and is available under different brand names such as Salamol, Ventolin, and Proventil. The usage of short-acting beta-2-agonists SABAs on a regular basis for at least seven days in stable COPD is associated with the decrease in breathlessness...
View full press release